BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Официальное название

BILMOD: BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention

Обзор

This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer.

Подробное описание

In this research study, the investigators are:

* Investigating the effect of more plant-based and less animal-based food intake on bile acid metabolomic composition in stool among individuals with a history of colorectal adenoma. * Investigating the effect of more plant-based and less animal-based food intake on plasma bile acid metabolomic composition, the gut microbiome, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer among individuals with a history of colorectal adenoma.

Based on the following evidence:

* Growing evidence indicates that the gut microbiome and its metabolites play important roles in mediating the dietary effects on colorectal cancer risk * Secondary bile acids are increasingly appreciated as important metabolites underlying the metabolic link between Western diet, the gut microbiome, and colorectal cancer * Evidence suggests that secondary bile acids trigger a plethora of tumorigenic effects in the colon, including inflammation, oxidative DNA damage, and apoptosis resistance * Epidemiological studies have revealed that a higher circulating level of secondary bile acids, particularly deoxycholic acid and lithocholic acid, was associated with an increased risk of colorectal cancer * High fat intake has been repeatedly reported to increase secondary bile acids, but the findings on how other nutrients or foods in Western diet may influence secondary bile acids remain mixed

The research procedures include screening for eligibility, study intervention, and scheduling two clinical research visits:

* Initial visit - immediately before starting the dietary intervention * 1 week of observation prior to dietary intervention * 4 weeks of dietary intervention (increasing plant based food and reducing animal-based food) * Final visit (after completing the dietary intervention)

At the Initial and Final visits, there will be a collection of lifestyle and nutritional questionnaire data, blood samples, and stool samples. The initial visit will establish the baseline data. The 1-week pre-intervention observation will establish baseline food diary data (every 2 days). The 4-week intervention phase will involve phone calls from study staff to guide participants in their diet changes, additional food diary entries (every 2 days), stool sample collection (every 7 days), and body weight reporting (every 7 days).

It is expected that about 40 people will take part in this research study.

This research is being supported by the National Cancer Institute.

Вмешательства

• Поведенческое Increased Plant-Based Diet and Decreased Animal-Based Diet
  Self-regulated diet; increased plant-based foods with decreased animal-based foods

Первичные конечные точки

• Change in Stool Metabolomics [Срок оценки: From Baseline to Final Visit (5 weeks)]

Вторичные конечные точки (1)

• Relative Composition of Gut Microbiome [Срок оценки: From Baseline to Final Visit (5 weeks)]

Критерии участия

Критерии включения

• Underwent screening or surveillance colonoscopy with removal of at least one adenoma.
• Age 18-80 years.
• Habitually consume a Western pattern diet.
• BMI of at least 18.5 kg/m2 but less than 35 kg/m2
• Weight stable in last 3 months (loss or gain <4%).
• Subjects must be able and willing to follow study procedures and instructions.
• Ability to understand and the willingness to sign a written informed consent document.

Критерии исключения

• Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.).
• Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis.
• Any prior diagnosis of gastrointestinal cancer (including esophageal, small intestine, colon, pancreatic), or any diagnosis of other cancers (with the exception of nonmelanoma skin) in which there has been any active treatment within the last three years.
• Known diagnosis of Familial Adenomatous Polyposis (FAP) or Hereditary Non-Polyposis Colorectal Cancer (HNPCC, Lynch Syndrome).
• Any adenoma that was not completely removed during previous colonoscopy.
• Known bleeding tendency/condition (e.g. von Willebrand disease) or history of peptic ulcer or gastrointestinal bleed requiring hospitalization, endoscopic complications, or contraindication to colonoscopy.
• Current use of anticoagulant therapies, including Heparin, Warfarin, Dalteparin sodium, Bivalirudin, Argatroban, Lepirudin, Heparin Sodium, Heparin/Dextrose, and an unwillingness or inability to discontinue anticoagulants.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Regular use of aspirin.
• Use of antibiotics or probiotics.
• Inability or unwillingness to abstain from limited consumption of animal-based food or to provide blood or stool samples during the study.
• Participants who are receiving any other investigational agents.
• Pregnant or breastfeeding.
• Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Профилактика

Центры проведения

США · 1 центр

• Massachusetts General Hospital Cancer Center — Boston

Идентификаторы

NCT: NCT07162337 · 25-611

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗